The neutrophil, not the tumor: Serum CA 15-3 elevation as a result of granulocyte-colony-stimulating factor-induced neutrophil MUC1 overexpression and neutrophilia in patients with breast carcinoma receiving adjuvant chemotherapy

Cancer

Volumn 101, Issue 8, 2004, Pages 1767-1775

  Pentheroudakis, George ^a   Malamou Mitsi, Vassiliki ^a   Briasoulis, Evangelos ^a   Damala, Konstantina ^a   Vassou, Amalia ^a   Vartholomatos, George ^a   Kolaitis, Nikos ^a   Pavlidis, Nikolas ^a,b  

^a UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

^b Institute of Biomedical Research   (Greece)

Author keywords

Breast carcinoma; CA 15 3; Chemotherapy; Granulocyte colony stimulating factor (G CSF); MUC1

Indexed keywords

BLEOMYCIN; CA 15-3 ANTIGEN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; METHOTREXATE; MUCIN 1; PACLITAXEL; PREDNISONE; PROCARBAZINE; VINCRISTINE;

ADULT; AGED; ARTICLE; BONE MARROW CELL; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CELL MEMBRANE; CLINICAL ARTICLE; CYTOPLASM; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNOCYTOCHEMISTRY; LYMPHOMA; MALE; MASTECTOMY; NEUTROPHIL; NEUTROPHILIA; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADENOCARCINOMA; ADULT; AGED; BONE MARROW; BREAST NEOPLASMS; CA-15-3 ANTIGEN; CARCINOMA, DUCTAL; CHEMOTHERAPY, ADJUVANT; FEMALE; FLOW CYTOMETRY; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEUTROPHILS; PROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 4744352268     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.20581     Document Type: Article

References (22)

1. Landis SH, Murray T, Bolden S, et al. Cancer statistics, 1999. CA Cancer J Clin. 1999;49:8-31.
2. Citron ML, Berry DA, Cirrincione C, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as post-operative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup trial C9741/CALCB 9741. J Clin Oncol. 2003;21:1-9.
3. Stearns V, Yamauchi H, Hayes D. Circulating tumor markers in breast cancer: accepted utilities and novel aspects. Recent Cancer Res Treat. 1998;52:239-259.
4. Briasoulis E, Andreopoulou E, Tolis C, et al. GCSF induces elevation of circulating CA 15-3 in breast carcinoma patients treated in an adjuvant setting. Cancer. 2001;91:909-917.
5. Zotter S, Hageman PC, Lossnitzer A, Mooi WJ, Hilgers J. Tissue and tumor distribution of human polymorphic epithelial mucin. Cancer Rev. 1988;11:55-101.
6. Taylor-Papadimitriou J, Burchell J, Miles DW, Dalziel M. MUC1 and cancer. Acta Biochim Biophys. 1999;1455:301-313.
7. Gum JR. Mucin genes and the proteins they encode: structure, diversity and regulation. Am J Respir Cell Mol Biol 1992;7:557-564.
8. Colomer R, Ruibal A, Genolla J, et al. Circulating CA 15-3 levels in the postsurgical follow-up of breast cancer patients and in non-malignant diseases. Breast Cancer Res Treat. 1989;13:123-133.
9. Vogelzang NJ, Lange PH, Goldman A, Vessela RH, Fraley EE, Kennedy BJ. Acute changes of alpha-fetoprotein and human chorionic gonadotropin during induction chemotherapy of germ cell tumors. Cancer Res. 1982;42:4855-4861.
10. Pentheroudakis G, O'Neill VJ, Vasey P, Kaye SB. Spontaneous acute tumor lysis syndrome in patients with metastatic germ cell tumours. Support Care Cancer. 2001;9:554-557.
11. Tyshler LB, Longton GM, Ellis GK, Livingston RB. False positive tumor markers: elevation in patients with breast cancer on FAC-type chemotherapy and correlation with the development of hand and foot syndrome. Int J Biol Markers. 1996;11:203-206.
12. Calhoun DA, Lunoe M, Du Y, Christensen RD. Granulocyte colony-stimulating factor is present in human milk and its receptor is present in human fetal intestine [abstract]. Pediatrics/ 2000;105:e7.
13. Vandermolen DT, Gu Y. Human endometrial expression of granulocyte colony-stimulating factor (GCSF) and its receptor, stimulation of endometrial GCSF production by interleukin-1 beta, and GCSF inhibition of choriocarcinoma cell proliferation. Am J Reprod Immunol. 1996;36:278-284.
14. Demetri GD, Griffin JD. Granulocyte colony-stimulating factor and its receptor. Blood. 1991;78:2791-2808.
15. Dearnaley DP, Ormerod MG, Sloane JP, et al. Detection of isolated mammary carcinoma cells in marrow of patients with primary breast cancer. J R Soc Med. 1983;76:359-364.
16. Dent GA, Civalier CJ, Brecher ME, Bentley SA. MUC1 expression in hematopoietic tissues. Am J Clin Pathol. 1999;111:741-747.
17. Berois N, Varangot M, Aizen B, et al. Molecular detection of cancer cells in bone marrow and peripheral blood of patients with operable breast cancer. Comparison of CK19, MUC1 and CEA with RT-PCR. Eur J Cancer. 2000;36:717-723.
18. Diel IJ, Kaufmann M, Costa SD, et al. Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status. J Natl Cancer Inst. 1996;88:1652-1664.
19. Brugger W, Buhring HJ, Grunebach F, et al. Expression of MUC1 epitopes on normal bone marrow: implications for the detection of micrometastatic tumor cells. J Clin Oncol. 1999;17:1535-1544.
20. Cao Y, Karsten U, Hilgers J. Immunohistochemical characterization of a panel of 56 antibodies with normal human small intestine, colon and breast tissues. Tumor Biol. 1998;19(Suppl. 1):88-99.
21. Xing PX, Prenzoska J, Quelch K, McKenzie IFC. Second generation anti-MUC1 peptide monoclonal antibodies. Cancer Res. 1992;52:2310-2317.
22. Burchell J, Taylor-Papadimitriou J. Effect of modification of carbohydrate side chains on the reactivity of antibodies with core-protein epitopes of the MUC1 gene product. Epithelial Cell Biol. 1993;2:155-162.